Chris Benecchi Named Inventiva's New Chief Operating Officer

By Karen Roman

Inventiva S.A. (Nasdaq: IVA) said it designated Chris Benecchi as Chief Operating Officer, having previously served as Chief Executive Officer of Motric Bio (an Aditum Bio company).

Mr. Benecchi will lead the company’s operational side as Inventiva comes close to its NATiV3 Phase 3 study results of lanifibranor in MASH, expected for the last quarter of 2026, and also prepare for potential commercialization, it stated.

“As we approach our Phase 3 readout, we are preparing the company for the next stage of its evolution,” said Andrew Obenshain, Inventiva’s CEO. “Chris brings a valuable combination of commercial, operational and launch experience, with a proven track record of helping organizations bring promising medicines to patients.”

Cocrystal Pharma: The Strategic Reset Investors May Be Missing

Mr. Benecchi has 30 years of biopharmaceutical leadership experience across commercial, operational and enterprise roles, with a record of building organizations, preparing investigational medicines for launch, and leading cross-functional execution in competitive and access-challenged markets, Inventiva said.

Mr. Benecchi holds an MBA from Duke University’s Fuqua School of Business and a Bachelor of Arts from Colby College.